Semiconducting alternating multi-block copolymers via a di-functionalized macromonomer approach

A route to fully-conjugated semiconducting block copolymers is presented and the prototype exhibits nanoscopic phase domain separation and good mobility.

[Critical roles of matrix metalloproteinases secreted by leukemic cells in the pathogenesis of central nervous system leukemia]

目的

观察白血病细胞分泌的基质金属蛋白酶（MMP）-2和MMP-9对脑微血管内皮细胞（BMVEC）紧密连接蛋白ZO-1、claudin-5、occludin表达及对血脑屏障（BBB）通透性的影响，探讨MMP-2和MMP-9在中枢神经系统白血病（CNSL）发病机制中的作用。

方法

①实时定量PCR检测SHI-1、HL-60、U937细胞MMP-2、MMP-9基因的转录水平；明胶酶谱法检测细胞培养上清中MMP-2和MMP-9蛋白表达；体外穿膜实验观察各白血病细胞株的侵袭能力。②将原代人BMVEC接种于铺有Matrigel胶和纤维黏连蛋白包被的Transwell小室系统中，建立体外BBB模型。将蛋白酶抑制剂GM6001处理或未处理的SHI-1、HL-60、U937细胞或MMP-2/MMP-9基因沉默的SHI-1细胞接种于BBB模型的Transwell小室上层与BMVEC共培养，倒置相差显微镜观察BMVEC的形态变化，激光共聚焦显微镜观察紧密连接蛋白ZO-1、claudin-5和occludin的表达，计算白血病细胞的穿膜率。

结果

①SHI-1细胞表达较高转录水平的MMP-2和MMP-9及酶活性，且侵袭能力强于HL-60、U937细胞（P< 0.01）。②与HL-60、SHI-1和U937细胞共培养后，融合致密的BMVEC之间出现间隙、细胞呈单个生长，紧密连接蛋白ZO-1、claudin-5和occludin的表达明显下调，各白血病细胞均不同程度地穿过体外BBB进入Transwell小室下层。其中SHI-1细胞对BMVEC的形态改变及3种紧密连接蛋白的下调最为明显，穿膜率最高。GM6001明显抑制白血病细胞分泌MMP-2和MMP-9，使BMVEC的形态有所恢复，同时上调ZO-1、claudin-5和occludin的表达，降低了BBB的通透性。③用siRNA分别沉默MMP-2和MMP-9基因后，SHI-1细胞分泌MMP-2和MMP-9被抑制，SHI-1细胞穿膜率较沉默前分别下降43.64％和57.30%（P<0.01），ZO-1、claudin-5和occludin表达上调。

结论

白血病细胞株分泌的MMP-2和MMP-9能通过降解BMVEC紧密连接蛋白ZO-1、claudin-5和occludin而破坏BBB。

Childhood obesity patterns and relation to middle-age sleep apnoea risk: the Bogalusa Heart Study

BACKGROUND

Obese adults have a higher risk of obstructive sleep apnoea (OSA); however, the relationship between childhood obesity and adult OSA risk is unclear. Objectives This study aimed to examine overweight/obesity (OW) in childhood and risk of OSA in middle age.

METHODS

Childhood OW status was classified as never OW, weight cycling, persistent OW and incident OW. After 35 years of follow-up, high risk for OSA was determined by a positive score in ≥2 domains on the Berlin Questionnaire with obesity removed from scoring.

RESULTS

At initial assessment, mean (SD) age was 9.9 (2.9) years, and 23.9% were OW. Overall, 25.7% had scores indicating a high risk for OSA. Compared with participants who were never OW, those with persistent OW and incident OW were 1.36 (95%CI: 1.04-1.77) and 1.47 (1.11-1.96) times more likely to be high risk for OSA, after adjustment for multiple risk factors and adult OW status. Participants with an OW duration of 1-4 years, 5-8 years, and 8+ years were 0.96 (0.44-2.09), 1.20 (0.70-2.04) and 1.52 (1.22-1.90) times more likely to be high risk for OSA compared with those who were never OW (P for trend: 0.0002).

CONCLUSIONS

These results suggest that childhood OW is associated with a high risk of OSA in middle age.

Antisense locked nucleic acids targeting agrA inhibit quorum sensing and pathogenesis of community-associated methicillin-resistant Staphylococcus aureus

AIM

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is commonly associated with nonnosocomial skin and soft tissue infections due to its virulence, which is mainly controlled by the accessory gene regulator (agr) quorum sensing (QS) system. In this study (KFF)₃ K peptide-conjugated locked nucleic acids (PLNAs) targeting agrA mRNA were developed to inhibit agr activity and arrest the pathogenicity of CA-MRSA.

METHODS AND RESULTS

Two PLNAs were designed, and synthesized, after predicting the secondary structure of agrA mRNA. The influence on bacterial growth was tested using a growth curve assay. RT-qPCR, haemolysis assay, lactate dehydrogenase release assay and chemotaxis assay were used to evaluate the effects of the PLNAs on inhibiting agr QS. A mouse skin infection model was employed to test the protective effect of the PLNAs in vivo. None of the PLNAs were found to be bacteriostatic or bactericidal in vitro. However, one PLNA, PLNA34, showed strong ability to suppress expression of agrA and the effector molecule RNAIII in USA300 LAC strain. Furthermore, PLNA34 inhibited the expression of virulence genes that are upregulated by agr, including hla, psmα, psmβ and pvl. The haemolytic activity of the supernatants from PLNA34-treated bacteria was also dramatically reduced, as well as the capacity to lyse and recruit neutrophils. Moreover, PLNA34 showed high levels of protection in the CA-MRSA mouse skin infection model.

CONCLUSIONS

The anti-agrA PLNA34 can effectively inhibit the agr QS and suppress CA-MRSA pathogenicity.

SIGNIFICANCE AND IMPACT OF THE STUDY

agrA is a promising target for the development of antisense oligonucleotides to block agr QS.

Cytogenetic evaluation of cataract patients occupationally exposed to ionizing radiation in northeast China

Long-term radiation exposure is hazardous to health; late-onset effects of exposure to ionizing radiation (IR) pose risks to the lens, and are associated with other non-cancerous diseases. Individuals occupationally exposed to low-dose IR are prone to developing eye cataracts. Cytogenetic evaluations suggest that IR is associated with chromosomal aberrations in occupationally exposed individuals. However, data regarding the association between chromosomal aberrations in cataract patients and occupational exposure to IR is scarce. Therefore, we aimed to report the characteristics of chromosomal aberrations in cataract patients from a Chinese population, occupationally exposed to IR. We found that the average age and frequency of numerical chromosomal aberrations were significantly lower in the exposed patients as compared with that in the non-exposed patients. In addition, the frequencies of dicentric and acentric chromosomes were significantly higher in the exposed patients as compared with those in the non-exposed patients. Therefore, chronic occupational exposure to IR affects cataract development in the Chinese population. The age of cataract patients exposed to IR was significantly lower than the age of cataract onset in normal individuals. Based on this study, we suggest that there is an urgent need for improved radiation safety and eye protection in individuals exposed to IR in the work place.

Identification of Natural Infections in Sheep/Goats with HoBi-like Pestiviruses in China

The natural infections of HoBi-like pestiviruses in cattle have been reported in South America, Europe and Asia. In China, although the detections of HoBi-like pestivirus have been reported, the epidemiological investigation was limited. From January 2014 to October 2015, several flocks of sheep/goats in Henan province in central China suffered respiratory diseases which were recovered slowly after antibiotics treatment. To test whether it is the HoBi-like pestivirus caused this symptom, 49 serum samples and 22 nasal swabs were then collected for analysis by serology and RT-PCR. Serological result revealed that prevalence of pestivirus in small ruminants was 12.2% (6/49) in central China. Sequence analysis of partial 5'-UTR nucleotides of pestivirus-positive samples suggested that HoBi-like pestivirus might have circulated in sheep/goats of China for a period and have evolved into new genotype clusters. It is apparent that the study provides the molecular evidence of natural infections in goat/sheep species with HoBi-like pestiviruses in China.

The effects of a low-carbohydrate diet on appetite: A randomized controlled trial

BACKGROUND AND AIMS

The relationship between dietary macronutrient composition and appetite is controversial. We examined the effects of a year-long low-carbohydrate diet compared to a low-fat diet on appetite-related hormones and self-reported change in appetite.

METHODS AND RESULTS

A total of 148 adults with a body mass index 30-45 kg/m(2), who were free of diabetes, cardiovascular disease and chronic kidney disease at baseline were randomly assigned to either a low-carbohydrate diet (carbohydrate [excluding dietary fiber]<40 g/day; N = 75) or a low-fat diet (<30% energy from fat, <7% from saturated fat; N = 73). Participants in both groups attended individual and group dietary counseling sessions where they were provided the same behavioral curriculum and advised to maintain baseline levels of physical activity. Appetite and appetite-related hormones were measured at 0, 3, 6 and 12 months of intervention. At 12 months, mean changes (95% CI) in peptide YY were -34.8 pg/mL (-41.0 to -28.6) and in the low-carbohydrate group and -44.2 pg/mL (-50.4 to -38.0) in the low-fat group (net change: 9.54 pg/mL [0.6 to 18.2]; p = 0.036). Approximately 99% of dietary effects on peptide YY are explained by differences in dietary macronutrient content. There was no difference in change in ghrelin or self-reported change in appetite between the groups.

CONCLUSIONS

A low-fat diet reduced peptide YY more than a low-carbohydrate diet. These findings suggest that satiety may be better preserved on a low-carbohydrate diet, as compared to a low fat diet.

TRIAL REGISTRATION

clinicaltrials.gov Identifier: NCT00609271.

Measurement of the centrality dependence of the charged-particle pseudorapidity distribution in proton-lead collisions at [Formula: see text] TeV with the ATLAS detector

The centrality dependence of the mean charged-particle multiplicity as a function of pseudorapidity is measured in approximately 1 [Formula: see text]b[Formula: see text] of proton-lead collisions at a nucleon-nucleon centre-of-mass energy of [Formula: see text] [Formula: see text] using the ATLAS detector at the Large Hadron Collider. Charged particles with absolute pseudorapidity less than 2.7 are reconstructed using the ATLAS pixel detector. The [Formula: see text] collision centrality is characterised by the total transverse energy measured in the Pb-going direction of the forward calorimeter. The charged-particle pseudorapidity distributions are found to vary strongly with centrality, with an increasing asymmetry between the proton-going and Pb-going directions as the collisions become more central. Three different estimations of the number of nucleons participating in the [Formula: see text] collision have been carried out using the Glauber model as well as two Glauber-Gribov inspired extensions to the Glauber model. Charged-particle multiplicities per participant pair are found to vary differently for these three models, highlighting the importance of including colour fluctuations in nucleon-nucleon collisions in the modelling of the initial state of [Formula: see text] collisions.

Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis

BACKGROUND

Paroxetine is the first non-hormone therapy for vasomotor symptoms (VMS) approved based on the results of two phase 3, randomised, placebo-controlled trials by the Food and Drug Administration (FDA) in 2013.

OBJECTIVE

To confirm the effect and safety of paroxetine for vasomotor symptoms (VMS).

SEARCH STRATEGY

MEDLINE, EMBASE, PsycINFO, CENTRAL, WHO International Clinical Trials Registry Platform (ICTRP) and four Chinese databases was searched from the date of their inception to 7 June 2014.

SELECTION CRITERIA

We included RCTs on the effect of paroxetine compared with placebo or no treatment for perimenopausal and postmenopausal women who experienced moderate-to-severe vasomotor symptoms.

DATA COLLECTION AND ANALYSIS

Two reviewers screened records and extracted the information independently. The included studies were appraised by two independent reviewers using the Cochrane risk of bias tool. We synthesised the data in random-effects models and rated the quality of evidence using GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.

MAIN RESULTS

Five articles with six RCTs (1571 participants) were included. Paroxetine significantly reduced the frequency of hot flushes by 8.86 per week (95% confidence interval (CI) 5.69-12.04, P < 0.00001, I(2)  = 83%) at week 4 and 7.36 per week (95% CI, 4.25-10.46, P < 0.00001, I(2)  = 62%) at week 12. The quality of the evidence on the effect of paroxetine for VMS was moderate.

CONCLUSIONS

There was moderate quality of evidence supporting the effectiveness of paroxetine for vasomotor symptoms; however, it causes nausea and dizziness.

TWEETABLE ABSTRACT

Review finds paroxetine effective for menopausal symptoms with some side effects: evidence strength moderate.

Hypoxia stimulates the proliferation of rat neural stem cells by regulating the expression of metabotropic glutamate receptors: an in vitro study

Neural stem cells (NSCs) reside in not only developing, but also adult brain with specialized microenvironments that regulate their function. In vitro and in vivo studies have revealed strong regulatory links between hypoxic/ischemic insults and activation of NSCs. However, the underlying mechanisms remain unclear. Here, we show that proliferating NSCs isolated from rat E15.5 cortex expressed functional metabotropic glutamate receptor (mGluR) subtype 3-7. Hypoxic exposure regulated their expression in NSCs in mRNA and protein levels. Activation of mGluRs by glutamate or Trans-ACPD (a non subtype-selective mGluRs agonist) sensitized NSCs to the growth effects of hypoxia. Pharmacological blockade of ionotropic glutamate receptor (iGluR) using MK-801 did not attenuate the action of glutamate in NSCs. Furthemore, we used the group specific mGluR agonists DHPG, LY 379268 and L-AP4 to explore which mGluR subtypes are responsible for stimulating NSCs proliferation after hypoxia. The results suggested that hypoxia increased expression of group I mGluR5 and significantly enhanced the NSCs proliferation. We conclude that hypoxia regulates the expression of mGluRs in proliferating NSCs and the dynamic expression of mGluRs induced by hypoxia may be one of the mechanisms of hypoxia stimulated NSCs activation. Regulation of mGluRs in NSCs might be a useful tool in the experimental cell therapy of hypoxic/ischemic injuries of CNS.

Advances in biological therapy for nucleus pulposus regeneration

OBJECTIVE

The intervertebral disc (IVD) is composed of the external annulus fibrosus (AF) and the inner gel-like center, the nucleus pulposus (NP). The elastic NP can function to relieve stress and maintain IVD function by distributing hydraulic pressure evenly to annulus and endplate. Degeneration of the NP, which leads to increased death of NP cells, the loss of proteoglycan (PG), and aberrant gene expression, may result in an overall alteration of the biomechanics of the spinal column and cause low back pain. Recent advances in biological therapy strategies that target therapy at the regeneration of degenerated and damaged NP have been investigated in in vitro and in vivo studies and demonstrated promising outcomes. In this article, we review recent studies of biological approaches for NP regeneration.

METHOD

The articles regarding NP regeneration using biomaterials, stem cells, and gene vectors were identified in PubMed databases.

RESULTS

Stem cell-mediated cell therapy demonstrates the potential to restore the function and structure of the NP. The viral or non-viral vectors encoding functional genes may generate a therapeutic effect when they are introduced into grafted cells or native cells in the NP. Biomaterial scaffolds generate an initial permissive environment for cell growth and allow the remodeling of scaffolds in the regeneration process. Biomaterial scaffolds provide structural support for NP regeneration and serve as a carrier for stem cell and gene vector delivery.

CONCLUSION

Though recent studies advance the body of knowledge needed to treat degenerated discs, many challenges need to be overcome before the application of these approaches can be successful clinically.

Denis RD, Staerz S, Stahlman J, Stamen R, Stamm S, Stanecka E, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark J, Staroba P, Starovoitov P, Staszewski R, Stavina P, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stern S, Stewart GA, Stillings JA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strandlie A, Strauss E, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Subramaniam R, Succurro A, Sugaya Y, Suhr C, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun S, Sun X, Sundermann JE, Suruliz K, Susinno G, Sutton MR, Suzuki S, Suzuki Y, Svatos M, Swedish S, Swiatlowski M, Sykora I, Sykora T, Ta D, Taccini C, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takeda H, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tam JYC, Tan KG, Tanaka J, Tanaka R, Tanaka S, Tannenwald BB, Tannoury N, Tapprogge S, Tarem S, Tarrade F, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor FE, Taylor GN, Taylor W, Teischinger FA, Teixeira Dias Castanheira M, Teixeira-Dias P, Temming KK, Ten Kate H, Teng PK, Teoh JJ, Tepel F, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Therhaag J, Theveneaux-Pelzer T, Thomas JP, Thomas-Wilsker J, Thompson EN, Thompson PD, Thompson RJ, Thompson AS, Thomsen LA, Thomson E, Thomson M, Thun RP, Tibbetts MJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tiouchichine E, Tipton P, Tisserant S, Todorov T, Todorova-Nova S, Tojo J, Tokár S, Tokushuku K, Tollefson K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Trefzger T, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Troncon C, Trottier-McDonald M, Trovatelli M, True P, Truong L, Trzebinski M, Trzupek A, Tsarouchas C, Tseng JCL, Tsiareshka PV, Tsionou D, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tudorache A, Tudorache V, Tuna AN, Tupputi SA, Turchikhin S, Turecek D, Turra R, Turvey AJ, Tuts PM, Tykhonov A, Tylmad M, Tyndel M, Ueda I, Ueno R, Ughetto M, Ugland M, Uhlenbrock M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urban J, Urquijo P, Urrejola P, Usai G, Usanova A, Vacavant L, Vacek V, Vachon B, Valderanis C, Valencic N, Valentinetti S, Valero A, Valery L, Valkar S, Valladolid Gallego E, Vallecorsa S, Valls Ferrer JA, Van Den Wollenberg W, Van Der Deijl PC, van der Geer R, van der Graaf H, Van Der Leeuw R, van Eldik N, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vanguri R, Vaniachine A, Vannucci F, Vardanyan G, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vazeille F, Vazquez Schroeder T, Veatch J, Veloce LM, Veloso F, Velz T, Veneziano S, Ventura A, Ventura D, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigne R, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Vivarelli I, Vives Vaque F, Vlachos S, Vladoiu D, Vlasak M, Vogel M, Vokac P, Volpi G, Volpi M, von der Schmitt H, von Radziewski H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vuillermet R, Vukotic I, Vykydal Z, Wagner P, Wagner W, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang K, Wang R, Wang SM, Wang T, Wang X, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Warsinsky M, Washbrook A, Wasicki C, Watkins PM, Watson AT, Watson IJ, Watson MF, Watts G, Watts S, Waugh BM, Webb S, Weber MS, Weber SW, Webster JS, Weidberg AR, Weinert B, Weingarten J, Weiser C, Weits H, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Wessels M, Wetter J, Whalen K, Wharton AM, White A, White MJ, White R, White S, Whiteson D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik-Fuchs LAM, Wildauer A, Wilkens HG, Williams HH, Williams S, Willis C, Willocq S, Wilson A, Wilson JA, Wingerter-Seez I, Winklmeier F, Winter BT, Wittgen M, Wittkowski J, Wollstadt SJ, Wolter MW, Wolters H, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wu M, Wu M, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xu D, Xu L, Yabsley B, Yacoob S, Yakabe R, Yamada M, Yamaguchi Y, Yamamoto A, Yamamoto S, Yamanaka T, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang Y, Yao L, Yao WM, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yen AL, Yildirim E, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJS, Youssef S, Yu DR, Yu J, Yu JM, Yu J, Yuan L, Yurkewicz A, Yusuff I, Zabinski B, Zaidan R, Zaitsev AM, Zalieckas J, Zaman A, Zambito S, Zanello L, Zanzi D, Zeitnitz C, Zeman M, Zemla A, Zengel K, Zenin O, Ženiš T, Zerwas D, Zhang D, Zhang F, Zhang J, Zhang L, Zhang R, Zhang X, Zhang Z, Zhao X, Zhao Y, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou C, Zhou L, Zhou L, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann S, Zinonos Z, Zinser M, Ziolkowski M, Živković L, Zobernig G, Zoccoli A, zur Nedden M, Zurzolo G, Zwalinski L. Measurements of the Higgs boson production and decay rates and coupling strengths using pp collision data at [Formula: see text] and 8 TeV in the ATLAS experiment

Combined analyses of the Higgs boson production and decay rates as well as its coupling strengths to vector bosons and fermions are presented. The combinations include the results of the analyses of the [Formula: see text] and [Formula: see text] decay modes, and the constraints on the associated production with a pair of top quarks and on the off-shell coupling strengths of the Higgs boson. The results are based on the LHC proton-proton collision datasets, with integrated luminosities of up to 4.7 [Formula: see text] at [Formula: see text] TeV and 20.3 [Formula: see text] at [Formula: see text] TeV, recorded by the ATLAS detector in 2011 and 2012. Combining all production modes and decay channels, the measured signal yield, normalised to the Standard Model expectation, is [Formula: see text]. The observed Higgs boson production and decay rates are interpreted in a leading-order coupling framework, exploring a wide range of benchmark coupling models both with and without assumptions on the Higgs boson width and on the Standard Model particle content in loop processes. The data are found to be compatible with the Standard Model expectations for a Higgs boson at a mass of 125.36 GeV for all models considered.

Denis RD, Staerz S, Stahlman J, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark J, Staroba P, Starovoitov P, Staszewski R, Stavina P, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stern S, Stewart GA, Stillings JA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strandlie A, Strauss E, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Subramaniam R, Succurro A, Sugaya Y, Suhr C, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun S, Sun X, Sundermann JE, Suruliz K, Susinno G, Sutton MR, Suzuki Y, Svatos M, Swedish S, Swiatlowski M, Sykora I, Sykora T, Ta D, Taccini C, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takeda H, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tam JYC, Tan KG, Tanaka J, Tanaka R, Tanaka S, Tanaka S, Tanasijczuk AJ, Tannenwald BB, Tannoury N, Tapprogge S, Tarem S, Tarrade F, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor FE, Taylor GN, Taylor W, Teischinger FA, Teixeira Dias Castanheira M, Teixeira-Dias P, Temming KK, Ten Kate H, Teng PK, Teoh JJ, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Therhaag J, Theveneaux-Pelzer T, Thomas JP, Thomas-Wilsker J, Thompson EN, Thompson PD, Thompson PD, Thompson RJ, Thompson AS, Thomsen LA, Thomson E, Thomson M, Thong WM, Thun RP, Tian F, Tibbetts MJ, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tiouchichine E, Tipton P, Tisserant S, Todorov T, Todorova-Nova S, Toggerson B, Tojo J, Tokár S, Tokushuku K, Tollefson K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Topilin ND, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Tran HL, Trefzger T, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Troncon C, Trottier-McDonald M, Trovatelli M, True P, Trzebinski M, Trzupek A, Tsarouchas C, Tseng JCL, Tsiareshka PV, Tsionou D, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tudorache A, Tudorache V, Tuna AN, Tupputi SA, Turchikhin S, Turecek D, Turra R, Tuts PM, Tykhonov A, Tylmad M, Tyndel M, Uchida K, Ueda I, Ueno R, Ughetto M, Ugland M, Uhlenbrock M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urbaniec D, Urquijo P, Usai G, Usanova A, Vacavant L, Vacek V, Vachon B, Valencic N, Valentinetti S, Valero A, Valery L, Valkar S, Valladolid Gallego E, Vallecorsa S, Valls Ferrer JA, Van Den Wollenberg W, Van Der Deijl PC, van der Geer R, van der Graaf H, Van Der Leeuw R, van der Ster D, van Eldik N, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vanguri R, Vaniachine A, Vannucci F, Vardanyan G, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vazeille F, Vazquez Schroeder T, Veatch J, Veloso F, Velz T, Veneziano S, Ventura A, Ventura D, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigne R, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Virzi J, Vivarelli I, Vives Vaque F, Vlachos S, Vladoiu D, Vlasak M, Vogel A, Vogel M, Vokac P, Volpi G, Volpi M, von der Schmitt H, von Radziewski H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vu Anh T, Vuillermet R, Vukotic I, Vykydal Z, Wagner P, Wagner W, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wall R, Waller P, Walsh B, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang K, Wang R, Wang SM, Wang T, Wang X, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Warsinsky M, Washbrook A, Wasicki C, Watkins PM, Watson AT, Watson IJ, Watson MF, Watts G, Watts S, Waugh BM, Webb S, Weber MS, Weber SW, Webster JS, Weidberg AR, Weigell P, Weinert B, Weingarten J, Weiser C, Weits H, Wells PS, Wenaus T, Wendland D, Weng Z, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Wessels M, Wetter J, Whalen K, White A, White MJ, White R, White S, Whiteson D, Wicke D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik-Fuchs LAM, Wijeratne PA, Wildauer A, Wildt MA, Wilkens HG, Will JZ, Williams HH, Williams S, Willis C, Willocq S, Wilson A, Wilson JA, Wingerter-Seez I, Winklmeier F, Winter BT, Wittgen M, Wittig T, Wittkowski J, Wollstadt SJ, Wolter MW, Wolters H, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wright M, Wu M, Wu SL, Wu X, Wu Y, Wulf E, Wyatt TR, Wynne BM, Xella S, Xiao M, Xu D, Xu L, Yabsley B, Yacoob S, Yakabe R, Yamada M, Yamaguchi H, Yamaguchi Y, Yamamoto A, Yamamoto K, Yamamoto S, Yamamura T, Yamanaka T, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang UK, Yang Y, Yanush S, Yao L, Yao WM, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yen AL, Yildirim E, Yilmaz M, Yoosoofmiya R, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJS, Youssef S, Yu DR, Yu J, Yu JM, Yu J, Yuan L, Yurkewicz A, Yusuff I, Zabinski B, Zaidan R, Zaitsev AM, Zaman A, Zambito S, Zanello L, Zanzi D, Zeitnitz C, Zeman M, Zemla A, Zengel K, Zenin O, Ženiš T, Zerwas D, Zevi della Porta G, Zhang D, Zhang F, Zhang H, Zhang J, Zhang L, Zhang X, Zhang Z, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou L, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann R, Zimmermann S, Zimmermann S, Zinonos Z, Ziolkowski M, Zobernig G, Zoccoli A, zur Nedden M, Zurzolo G, Zutshi V, Zwalinski L. Two-particle Bose-Einstein correlations in pp collisions at [Formula: see text] 0.9 and 7 TeV measured with the ATLAS detector

The paper presents studies of Bose-Einstein Correlations (BEC) for pairs of like-sign charged particles measured in the kinematic range [Formula: see text] 100 MeV and [Formula: see text] 2.5 in proton collisions at centre-of-mass energies of 0.9 and 7 TeV with the ATLAS detector at the CERN Large Hadron Collider. The integrated luminosities are approximately 7 [Formula: see text]b[Formula: see text], 190 [Formula: see text]b[Formula: see text] and 12.4 nb[Formula: see text] for 0.9 TeV, 7 TeV minimum-bias and 7 TeV high-multiplicity data samples, respectively. The multiplicity dependence of the BEC parameters characterizing the correlation strength and the correlation source size are investigated for charged-particle multiplicities of up to 240. A saturation effect in the multiplicity dependence of the correlation source size parameter is observed using the high-multiplicity 7 TeV data sample. The dependence of the BEC parameters on the average transverse momentum of the particle pair is also investigated.

Search for Dark Matter in Events with Missing Transverse Momentum and a Higgs Boson Decaying to Two Photons in pp Collisions at sqrt[s]=8 TeV with the ATLAS Detector

Results of a search for new phenomena in events with large missing transverse momentum and a Higgs boson decaying to two photons are reported. Data from proton-proton collisions at a center-of-mass energy of 8 TeV and corresponding to an integrated luminosity of 20.3 fb^{-1} have been collected with the ATLAS detector at the LHC. The observed data are well described by the expected standard model backgrounds. Upper limits on the cross section of events with large missing transverse momentum and a Higgs boson candidate are also placed. Exclusion limits are presented for models of physics beyond the standard model featuring dark-matter candidates.

Inflammatory dentigerous cyst of mandibular first premolar associated with endodontically treated primary first molar: a rare case report

AIM

Inflammatory dentigerous cysts usually occur in the mixed dentition. It has been reported that inflammatory lesions from the root area of a deciduous tooth bring about the development of dentigerous cysts around the unerupted permanent tooth bud. Endodontic treatment is a common and successful procedure for periapical inflammation in children. An inflammatory dentigerous cyst can occur in conjunction with endodontically treated primary tooth.

CASE REPORT

This article reports a case of 6 years and 6 months old boy, with a single, well-defined, unilocular, radiolucent area enclosing the first right unerupted mandibular premolar, accidentally discovered on the panoramic radiograph. The first right primary molar had received a root canal treatment 18 months prior. Clinical findings combined with radiographic and microscopic examinations confirmed the diagnosis of inflammatory dentigerous cyst. As treatment, enucleation of the cyst with removal of the involved permanent tooth was chosen and a removable partial denture was supplied to the patient after surgery. The 5-year follow-up revealed good healing of the bony lesion and displaced teeth.

CONCLUSION

This case presented a severe and rare complication of endodontically treated primary tooth, and the recommendation includes: (1) early diagnosis of dentigerous cysts, which is essential to prevent extensive treatment; (2) more information on the adverse side effects of an endodontic treatment should be given to patients and parents; (3) patients should be informed about the importance of follow-ups and radiographic follow-up should be routinised.

Measurements of the Total and Differential Higgs Boson Production Cross Sections Combining the H→γγ and H→ZZ^{*}→4ℓ Decay Channels at sqrt[s]=8 TeV with the ATLAS Detector

Measurements of the total and differential cross sections of Higgs boson production are performed using 20.3  fb^{-1} of pp collisions produced by the Large Hadron Collider at a center-of-mass energy of sqrt[s]=8  TeV and recorded by the ATLAS detector. Cross sections are obtained from measured H→γγ and H→ZZ^{*}→4ℓ event yields, which are combined accounting for detector efficiencies, fiducial acceptances, and branching fractions. Differential cross sections are reported as a function of Higgs boson transverse momentum, Higgs boson rapidity, number of jets in the event, and transverse momentum of the leading jet. The total production cross section is determined to be σ_{pp→H}=33.0±5.3 (stat)±1.6 (syst)  pb. The measurements are compared to state-of-the-art predictions.